Pharmaceuticals

Proving Plausibility – Can Post-filed Evidence Support your Patent: Part 2

  As we found in the first part of this two-part series, timing is everything when it comes to filing a patent application. Filing too early may mean your application may lack the essential evidence to support your invention. But can post-filed data resuscitate your chances of a patent? In...

Read more

Proving Plausibility – How a Deficient Disclosure can be Terminal for a Patent: Part 1

  Timing is everything when it comes to filing a patent application. Too early and your application may lack the essential evidence to support your invention. Too late and the competition may beat you to it. But problems may arise if suitable evidence is not included in your patent application,...

Read more

Neurodegenerative Disease: Is Your IP Strategy Setting You Up for Success?

With an ever-aging population, one of the biggest challenges facing the modern world is the rising prevalence of neurodegenerative disease. Neurodegenerative disease is a collective term for a number of diseases characterised by the loss of structure, or function, of neurons; the building blocks of the nervous system. Examples of...

Read more

Santen: A clear view of drug repurposing and a loss of sleep for those relying on Neurim

The CJEU has dealt a massive blow to the drug repurposing sector with its decision in Santen, stripping companies of their right to Supplementary Protection Certificates (SPCs), and overturning one of the most influential SPC cases of all time: Neurim. SPCs provide up to five years of market exclusivity for...

Read more

Wisdom of the crowd: how to make sure IP doesn’t derail your crowdfunding efforts

Startups raising hundreds of thousands – even millions – of pounds via Kickstarter may be rarer than it once was, but crowdfunding remains a popular method of fundraising. There are a myriad of options, whether you go down the equity crowdfunding route offered by the likes of Seedrs, CrowdCube, and...

Read more